Progress of tamsulosin hydrochloride sustained-release preparation

CHAI Peihua; ZHANG Tao; GAO Shen

doi:10.3969/j.issn.1006-0111.2016.06.004

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Tamsulosin hydrochloride is widely used for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia, requiring long-term medication. It reduces adverse reactions of hypotension and dizziness by rapid absorption from oral intake. The sustained-release (SR) formulation is recommended for clinical application. Currently in domestic and foreign market, SR products mainly include SR capsules and SR tablets, like Flomax^® and Harnal^®. The domestic market mainly uses the originally developed Harnal^® SR capsules. In accordance with the drug's potential market, more and more SR studies have been done. This article reviews the research progress of tamsulosin hydrochloride sustained-release preparation.

Progress of tamsulosin hydrochloride sustained-release preparation

1. Department of Pharmacy, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China;Evonik Specialty Chemicals(Shanghai) Co., Ltd., Shanghai 201108, China

2. Evonik Specialty Chemicals(Shanghai) Co., Ltd., Shanghai 201108, China

3. Department of Pharmacy, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China

Received Date: 2015-10-21

Rev Recd Date: 2016-04-26

Key words:

tamsulosin hydrochloride(TSH) /
sustained-release preparation

Abstract: Tamsulosin hydrochloride is widely used for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia, requiring long-term medication. It reduces adverse reactions of hypotension and dizziness by rapid absorption from oral intake. The sustained-release (SR) formulation is recommended for clinical application. Currently in domestic and foreign market, SR products mainly include SR capsules and SR tablets, like Flomax^® and Harnal^®. The domestic market mainly uses the originally developed Harnal^® SR capsules. In accordance with the drug's potential market, more and more SR studies have been done. This article reviews the research progress of tamsulosin hydrochloride sustained-release preparation.

HTML

Reference (14)

[1]	Kim JS, Kim MS, Park HJ,et al. Statistical optimization of tamsulosin hydrochloridecontrolled release pellets coated with the blend of HPMCP and HPMC[J]. Chem Pharm Bull, 2007, 55(6):936-939.
[2]	杨颖,伍良涌,谭文非. 盐酸坦索罗辛缓释片含量和释放度测定方法研究[J]. 今日药学,2013,23(1):26-29.
[3]	朱彩燕,沈映冰,吕永丰,等. 离心造粒法制备盐酸坦索罗辛缓释微丸胶囊的工艺影响因素及体外释放度考察[J]. 中国药房,2011,22(13):1196-1199.
[4]	李昌其,杨继斌,石森林,等. 盐酸坦索罗辛缓释微丸胶囊的制备及处方工艺考察[J]. 上海医药,2012,33(21):45-48.
[5]	邢小敏,梁超峰,吴淳,等. LC-MS/MS法测定坦索罗辛在比格犬血浆中的浓度及其缓释制剂的药动学研究[J]. 中国临床药理学与治疗学,2011,16(8):884-889.
[6]	郭新颖. 盐酸坦索洛新凝胶骨架缓释片剂的设计与评价[D]. 沈阳:沈阳药科大学,2000.
[7]	Park JS, Shim JY, Park JS, et al. Formulation variationand in vitro-in vivo correlation for a rapidly swellable three-layered tablet of tamsulosin HCl[J]. Chem Pharm Bull,2011, 59(5):529-535.
[8]	北京红林制药有限公司. 一种盐酸坦洛新控释片制剂及其制备方法:CN101147729A[P]. 2008-03-26.
[9]	西梯茜生命工学股份有限公司. 含盐酸坦索罗辛的控释制剂:CN101128190A[P]. 2008-02-20.
[10]	山之内制药株式会社. 改善下腹和/或会阴疼痛的治疗剂:CN1694692A[P]. 2005-11-09.
[11]	兰贝克赛实验室有限公司. 坦洛新的控释药物组合物:CN1744889A[P]. 2006-03-08.
[12]	江苏大学,扬子江药业集团有限公司. 盐酸坦索罗辛缓释微丸制剂及其制备方法:CN101695478A[P]. 2010-04-21.
[13]	北京可信必诚医药科技发展有限公司. 一种盐酸坦索罗辛缓释微丸制剂及其制备方法:CN103315962A[P]. 2013-09-25.
[14]	Okuda Y, Okamoto Y, Irisawa Y, et al. Formulation design for orally disintegratingtablets containing enteric-coated particles[J]. Chem Pharm Bull, 2014, 62(5):407-414.

Message Board

Progress of tamsulosin hydrochloride sustained-release preparation

doi: 10.3969/j.issn.1006-0111.2016.06.004

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views